about
ERBB3: A potential serum biomarker for early detection and therapeutic target for devil facial tumour 1 (DFT1)Comparative analysis of plant-produced, recombinant dimeric IgA against cell wall β-glucan of pathogenic fungi.Cardiovascular Complications Associated With Novel Cancer Immunotherapies.T-lymphocyte homing: an underappreciated yet critical hurdle for successful cancer immunotherapy.Transfer of in vitro-expanded naïve T cells after lymphodepletion enhances antitumor immunity through the induction of polyclonal antitumor effector T cells.The immunomodulatory anticancer agent, RRx-001, induces an interferon response through epigenetic induction of viral mimicry.Anti-tumor effects of the American cockroach, Periplaneta americanaDGK-α: A Checkpoint in Cancer-Mediated Immuno-Inhibition and Target for Immunotherapy.Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group.STAT3-blocked whole-cell hepatoma vaccine induces cellular and humoral immune response against HCC.New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.Cardiotoxicity of Anticancer Therapeutics.Immunotherapy advances for mesothelioma treatment.Targeting Tumor Metabolism: A New Challenge to Improve Immunotherapy.Prognostic values of the mRNA expression of natural killer receptor ligands and their association with clinicopathological features in breast cancer patients.The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC).Disruption of PD-1 Enhanced the Anti-tumor Activity of Chimeric Antigen Receptor T Cells Against Hepatocellular CarcinomaChemokine Receptors and Exercise to Tackle the Inadequacy of T Cell Homing to the Tumor SiteImmune-related adverse events of immune checkpoint inhibitors: a brief reviewIntegrating Immunology and Microfluidics for Single Immune Cell Analysis
P2860
Q33772914-5F327226-15D7-4938-BDF3-2E87F9E89F52Q38612388-5C208FF3-7400-4C91-A30E-5F5124EB3D00Q38731522-A63295CC-728F-407F-8424-E32DDC5C3A60Q38873974-3FE325B0-0906-4611-98F6-6A57F026690DQ40074591-7FBD0305-58CF-465C-932B-4BD818EAD7BCQ40349579-6C127EA1-8E78-4CC6-A27E-A0FC16BB1DDBQ41154095-C68BE852-2130-4013-937F-5E5824CFB402Q41764893-F1FED1B8-EDAF-4320-B22D-B1FC1C45544CQ47102520-9A67611F-5439-421F-8D6E-C39377DF68D4Q47122059-783CBA57-C58D-4060-8C7E-FDE4399EA77FQ47221234-8203BE47-C139-4446-BEAC-E036AA87A4EEQ50326869-F08782A5-9772-445B-9DD2-D4148B4B5449Q51823843-B49B62DC-BC2F-475C-8BB0-D4445BF4E189Q52661722-54B12626-5868-44B8-85AB-4BD6A7CED24DQ55405564-A45D7979-9285-4796-8FD4-4CAA1464090FQ55717841-F640AE39-A2BD-4702-9306-4125B9235588Q57486613-85B3DA45-67A5-41D8-9701-C83C8B879465Q58768316-BB7B641B-BCD5-450E-9D22-57E45D349BCAQ59126189-1FAC35A2-7C78-4956-B499-9F71515ED238Q59136363-146A9D12-7C21-4F07-8D86-B2723F950389
P2860
description
2016 nî lūn-bûn
@nan
2016 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2016 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
Harnessing the immune system to improve cancer therapy
@ast
Harnessing the immune system to improve cancer therapy
@en
Harnessing the immune system to improve cancer therapy
@nl
type
label
Harnessing the immune system to improve cancer therapy
@ast
Harnessing the immune system to improve cancer therapy
@en
Harnessing the immune system to improve cancer therapy
@nl
prefLabel
Harnessing the immune system to improve cancer therapy
@ast
Harnessing the immune system to improve cancer therapy
@en
Harnessing the immune system to improve cancer therapy
@nl
P2093
P2860
P356
P1476
Harnessing the immune system to improve cancer therapy
@en
P2093
Nikos E Papaioannou
Ourania Tsitsilonis
Ourania V Beniata
Panagiotis Vitsos
Pinelopi Samara
P2860
P356
10.21037/ATM.2016.04.01
P407
P577
2016-07-01T00:00:00Z